Sapna Srivastava
Lead Independent DirectorDr. Sapna Srivastava, Ph.D. served as an Independent Director of Innoviva, Inc. since January 01, 2023 until May 19, 2025. She serves as an Independent Director at Alumis Inc. since August 2022 and as its lead independent director from June 2025. She was independent Director at Tourmaline Bio, Inc. until October 28, 2025. Dr. Srivastava served as Interim Chief Financial Officer at Egenesis Inc. since March 2021 until October 2021. Dr. Social has been an Independent Director of Social Capital Suvretta Holdings Corp. II since June 29, 2021. She served as an Independent Non-Executive Director of Nuvalent, Inc. from July 2021 to July 15, 2026. She serves as an Independent Director of SQZ Biotechnologies Co. since October 2020. Dr. Srivastava serves as a Director at Aura Biosciences, Inc. since May 2021. Dr. Srivastava serves as a Director at AsclepiX Therapeutics, LLC since November 13, 2018. She has been an Independent Director at Talaris Therapeutics, Inc. since January 2021. Dr. Srivastava was Chief Financial and Strategy Officer of Abide Therapeutics Inc. since September 18, 2017 until January 2019. Abide Therapeutics was acquired by Lundbeck. She also served as a Director of VelosBio Incorporated from October 2020 to December 2020. Dr. Srivastava was a Senior Advisor of Intellia Therapeutics Inc. since December 2016 and served as its Chief Financial and Strategy Officer from April 2015 to December 2016. Dr. Srivastava is a veteran Wall Street Analyst and business strategy advisor in the biopharmaceutical industry. Dr. Srivastava has experience as a senior executive in the biopharmaceutical industry. Dr. Srivastava served as a Senior Advisor of MYOS Corporation from November 12, 2012 to February 8, 2013. She served as a Research Analyst at Goldman Sachs Group Inc. Research Division until June 14, 2012. As the Senior Analyst and team leader of the biotechnology group at Goldman Sachs, she established strong relationships with prominent industry influencers, including institutional Investors, policy makers and scientific thought leaders. Dr. Srivastava served as a Research Analyst at Morgan Stanley, Research Division. She served as Senior Biotechnology Analyst at Goldman Sachs, Morgan Stanley and ThinkEquity Partners, LLC. She began her career as a research associate at J.P. Morgan. She served as a Principal and Senior Research Analyst at ThinkEquity LLC (Formerly, ThinkPanmure LLC). Dr. Srivastava served at J.P. Morgan Chase & Co. from April 1999 to December 2002, covering the biotechnology sector. She served as an Equity Analyst at ThinkEquity LLC, Research Division and JP Morgan Chase & Co, Research Division. Dr. Srivastava served as an independent strategy advisor to biotech start-up companies and co-founded a neuroscience-focused biotechnology company. She served as an Independent Director of MYOS Corporation (alternate name: MYOS RENS Technology Inc.) from February 8, 2013 to March 11, 2016. She received B.S. in Biology from St. Xavier's College at the University of Mumbai and a Ph.D. in Neuroscience from New York University School of Medicine.
Positions
- Company NameAlumis Inc.Stock CodeALMSPositionLead Independent DirectorColleagues
- MBMartin BablerPresident, CEO & Chairman
- DMDavid M. GoldsteinChief Scientific Officer
- JDJorn DrappaChief Medical Officer & Head of Research and Development
- JRJohn R. SchroerChief Financial Officer
- SPSanam PangaliChief Legal Officer & Corporate Secretary
- ABAlan B. ColowickIndependent Director
- CPC. Patrick MachadoIndependent Director
- JBJames Bruce TananbaumIndependent Director
- Company NameAura Biosciences, Inc.Stock CodeAURAPositionIndependent DirectorColleagues
- JJJ. Jill HopkinsChief Medical Officer & President of Research and Development
- DMDavid Michael JohnsonIndependent Chairman of the Board
- NCNatalie C. HollesPresident, CEO & Director
- AEAmy ElazzouziSenior Vice President of Finance, Treasurer and Secretary
- SASusan Abu-AbsiChief Operating Officer
- ADAlex DasallaHead of Investor Relations & Corporate Communications
- GMGiovanni MariggiIndependent Director
- SSSapna SrivastavaIndependent Director
- AMAntony MattessichIndependent Director
